# Caci International Inc: financial statements, quarterly

CACI · NYSE · CIK 16058 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/caci.md) · [Financials](/companies/caci/financials.md) · [Filings](/companies/caci/filings.md) · [Insiders](/companies/caci/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/caci/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,834](/filings/0000016058-25-000032.md) | [1,937](/filings/0000016058-25-000053.md) | [2,038 d](/filings/0001628280-26-054195.md) | [2,057](/filings/0000016058-25-000087.md) | [2,100](/filings/0001628280-26-003026.md) | [2,167](/filings/0001628280-26-026802.md) | [2,304 d](/filings/0001628280-26-054195.md) | [2,288](/filings/0001628280-26-066827.md) | [2,220](/filings/0001628280-26-003026.md) | [2,351](/filings/0001628280-26-026802.md) | [2,709 d](/filings/0001628280-26-054195.md) | [2,475](/filings/0001628280-26-066827.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [409](/filings/0000016058-25-000032.md) | [430](/filings/0000016058-25-000053.md) | [476 d](/filings/0001628280-26-054195.md) | [428](/filings/0000016058-25-000087.md) | [467](/filings/0001628280-26-003026.md) | [481](/filings/0001628280-26-026802.md) | [457 d](/filings/0001628280-26-054195.md) | [474](/filings/0001628280-26-066827.md) | [465](/filings/0001628280-26-003026.md) | [510](/filings/0001628280-26-026802.md) | [563 d](/filings/0001628280-26-054195.md) | [550](/filings/0001628280-26-066827.md) |
| Operating income | $m | [133](/filings/0000016058-25-000032.md) | [181](/filings/0000016058-25-000053.md) | [198 d](/filings/0001628280-26-054195.md) | [180](/filings/0000016058-25-000087.md) | [181](/filings/0001628280-26-003026.md) | [196](/filings/0001628280-26-026802.md) | [207 d](/filings/0001628280-26-054195.md) | [212](/filings/0001628280-26-066827.md) | [206](/filings/0001628280-26-003026.md) | [229](/filings/0001628280-26-026802.md) | [272 d](/filings/0001628280-26-054195.md) | [248](/filings/0001628280-26-066827.md) |
| Interest expense | $m | [27.5](/filings/0000016058-24-000030.md) | [27.7](/filings/0000016058-24-000070.md) | [24.3 d](/filings/0001628280-26-054195.md) | [24.0](/filings/0000016058-25-000087.md) | [44.1](/filings/0001628280-26-003026.md) | [45.1](/filings/0001628280-26-026802.md) | [45.7 d](/filings/0001628280-26-054195.md) | [46.2](/filings/0001628280-26-066827.md) | [45.0](/filings/0001628280-26-003026.md) | [52.3](/filings/0001628280-26-026802.md) | [72.1 d](/filings/0001628280-26-054195.md) | [73.2](/filings/0001628280-26-066827.md) |
| Income tax | $m | [21.9](/filings/0000016058-25-000032.md) | [38.3](/filings/0000016058-25-000053.md) | [38.8 d](/filings/0001628280-26-054195.md) | [35.7](/filings/0000016058-25-000087.md) | [27.3](/filings/0001628280-26-003026.md) | [39.4](/filings/0001628280-26-026802.md) | [3.1 d](/filings/0001628280-26-054195.md) | [41.3](/filings/0001628280-26-066827.md) | [37.7](/filings/0001628280-26-003026.md) | [46.2](/filings/0001628280-26-026802.md) | [43.4 d](/filings/0001628280-26-054195.md) | [43.9](/filings/0001628280-26-066827.md) |
| Net income | $m | [83.9](/filings/0000016058-25-000032.md) | [115](/filings/0000016058-25-000053.md) | [135 d](/filings/0001628280-26-054195.md) | [120](/filings/0000016058-25-000087.md) | [110](/filings/0001628280-26-003026.md) | [112](/filings/0001628280-26-026802.md) | [158 d](/filings/0001628280-26-054195.md) | [125](/filings/0001628280-26-066827.md) | [124](/filings/0001628280-26-003026.md) | [130](/filings/0001628280-26-026802.md) | [157 d](/filings/0001628280-26-054195.md) | [130](/filings/0001628280-26-066827.md) |
| Diluted EPS | $ per share | [3.74](/filings/0000016058-25-000032.md) | [5.13](/filings/0000016058-25-000053.md) | not reported | [5.33](/filings/0000016058-25-000087.md) | [4.88](/filings/0001628280-26-003026.md) | [5.00](/filings/0001628280-26-026802.md) | not reported | [5.63](/filings/0001628280-26-066827.md) | [5.59](/filings/0001628280-26-003026.md) | [5.88](/filings/0001628280-26-026802.md) | not reported | [5.84](/filings/0001628280-26-066827.md) |
| Basic EPS | $ per share | [3.76](/filings/0000016058-25-000032.md) | [5.17](/filings/0000016058-25-000053.md) | not reported | [5.39](/filings/0000016058-25-000087.md) | [4.90](/filings/0001628280-26-003026.md) | [5.02](/filings/0001628280-26-026802.md) | not reported | [5.67](/filings/0001628280-26-066827.md) | [5.61](/filings/0001628280-26-003026.md) | [5.90](/filings/0001628280-26-026802.md) | not reported | [5.90](/filings/0001628280-26-066827.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.1](/filings/0000016058-24-000030.md) | [0.2](/filings/0000016058-24-000070.md) | [0.1](/filings/0001628280-25-038739.md) | [0.4](/filings/0000016058-24-000199.md) | [0.2](/filings/0000016058-25-000032.md) | [0.2](/filings/0000016058-25-000053.md) | [0.1](/filings/0001628280-26-054195.md) | [0.1](/filings/0000016058-25-000087.md) | [0.4](/filings/0001628280-26-003026.md) | [0.2](/filings/0001628280-26-026802.md) | [0.2](/filings/0001628280-26-066827.md) | [0.3](/filings/0001628280-26-066827.md) |
| Current assets | $bn | [1.3](/filings/0000016058-24-000030.md) | [1.4](/filings/0000016058-24-000070.md) | [1.4](/filings/0001628280-25-038739.md) | [1.7](/filings/0000016058-24-000199.md) | [1.6](/filings/0000016058-25-000032.md) | [1.7](/filings/0000016058-25-000053.md) | [1.8](/filings/0001628280-26-054195.md) | [1.9](/filings/0000016058-25-000087.md) | [2.1](/filings/0001628280-26-003026.md) | [2.0](/filings/0001628280-26-026802.md) | [2.3](/filings/0001628280-26-066827.md) | [2.4](/filings/0001628280-26-066827.md) |
| Total assets | $bn | [6.7](/filings/0000016058-24-000030.md) | [6.8](/filings/0000016058-24-000070.md) | [6.8](/filings/0001628280-25-038739.md) | [7.2](/filings/0000016058-24-000199.md) | [8.5](/filings/0000016058-25-000032.md) | [8.6](/filings/0000016058-25-000053.md) | [8.6](/filings/0001628280-26-054195.md) | [8.7](/filings/0000016058-25-000087.md) | [8.9](/filings/0001628280-26-003026.md) | [11.6](/filings/0001628280-26-026802.md) | [11.8](/filings/0001628280-26-066827.md) | [11.9](/filings/0001628280-26-066827.md) |
| Current liabilities | $bn | [1.0](/filings/0000016058-24-000030.md) | [1.1](/filings/0000016058-24-000070.md) | [1.1](/filings/0001628280-25-038739.md) | [1.0](/filings/0000016058-24-000199.md) | [1.1](/filings/0000016058-25-000032.md) | [1.1](/filings/0000016058-25-000053.md) | [1.2](/filings/0001628280-26-054195.md) | [1.2](/filings/0000016058-25-000087.md) | [1.1](/filings/0001628280-26-003026.md) | [1.3](/filings/0001628280-26-026802.md) | [1.5](/filings/0001628280-26-066827.md) | [1.5](/filings/0001628280-26-066827.md) |
| Total liabilities | $bn | [3.4](/filings/0000016058-24-000030.md) | [3.4](/filings/0000016058-24-000070.md) | [3.3](/filings/0001628280-25-038739.md) | [3.5](/filings/0000016058-24-000199.md) | [4.8](/filings/0000016058-25-000032.md) | [4.9](/filings/0000016058-25-000053.md) | [4.8](/filings/0001628280-26-054195.md) | [4.7](/filings/0000016058-25-000087.md) | [4.8](/filings/0001628280-26-003026.md) | [7.3](/filings/0001628280-26-026802.md) | [7.4](/filings/0001628280-26-066827.md) | [7.3](/filings/0001628280-26-066827.md) |
| Long-term debt | $bn | [1.7](/filings/0000016058-24-000030.md) | [1.6](/filings/0000016058-24-000070.md) | [1.5](/filings/0001628280-25-038739.md) | [1.8](/filings/0000016058-24-000199.md) | [3.0](/filings/0000016058-25-000032.md) | [3.0](/filings/0000016058-25-000053.md) | [2.8](/filings/0001628280-26-054195.md) | [2.7](/filings/0000016058-25-000087.md) | [2.9](/filings/0001628280-26-003026.md) | [5.1](/filings/0001628280-26-026802.md) | [4.9](/filings/0001628280-26-066827.md) | [4.8](/filings/0001628280-26-066827.md) |
| Current portion of debt | $bn | [0.1](/filings/0000016058-24-000030.md) | [0.1](/filings/0000016058-24-000070.md) | [0.1](/filings/0001628280-25-038739.md) | [0.1](/filings/0000016058-24-000199.md) | [0.1](/filings/0000016058-25-000032.md) | [0.1](/filings/0000016058-25-000053.md) | [0.1](/filings/0001628280-26-054195.md) | [0.1](/filings/0000016058-25-000087.md) | [0.0](/filings/0001628280-26-003026.md) | [0.0](/filings/0001628280-26-026802.md) | [0.0](/filings/0001628280-26-066827.md) | [0.0](/filings/0001628280-26-066827.md) |
| Shareholders' equity | $bn | [3.2](/filings/0000016058-24-000030.md) | [3.4](/filings/0000016058-24-000070.md) | [3.5](/filings/0000016058-25-000053.md) | [3.7](/filings/0000016058-24-000199.md) | [3.7](/filings/0000016058-25-000032.md) | [3.7](/filings/0000016058-25-000053.md) | [3.9](/filings/0001628280-26-066827.md) | [4.0](/filings/0001628280-26-066827.md) | [4.1](/filings/0001628280-26-026802.md) | [4.3](/filings/0001628280-26-026802.md) | [4.5](/filings/0001628280-26-066827.md) | [4.6](/filings/0001628280-26-066827.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [71.8 d](/filings/0000016058-25-000032.md) | [198 d](/filings/0000016058-25-000053.md) | [157 d](/filings/0001628280-26-054195.md) | [34.7](/filings/0000016058-25-000087.md) | [126 d](/filings/0001628280-26-003026.md) | [230 d](/filings/0001628280-26-026802.md) | [156 d](/filings/0001628280-26-054195.md) | [171](/filings/0001628280-26-066827.md) | [154 d](/filings/0001628280-26-003026.md) | [183 d](/filings/0001628280-26-026802.md) | [378 d](/filings/0001628280-26-054195.md) | [161](/filings/0001628280-26-066827.md) |
| Capital expenditure | $m | [15.4 d](/filings/0000016058-25-000032.md) | [11.7 d](/filings/0000016058-25-000053.md) | [22.6 d](/filings/0001628280-26-054195.md) | [11.5](/filings/0000016058-25-000087.md) | [9.9](/filings/0001628280-26-003026.md) | [16.2](/filings/0001628280-26-026802.md) | [28.0 d](/filings/0001628280-26-054195.md) | [17.0](/filings/0001628280-26-066827.md) | [16.0](/filings/0001628280-26-003026.md) | [26.8](/filings/0001628280-26-026802.md) | [46.8 d](/filings/0001628280-26-054195.md) | [11.4](/filings/0001628280-26-066827.md) |
| Share repurchases | $m | [15.4 d](/filings/0000016058-25-000032.md) | [2.7 d](/filings/0000016058-25-000053.md) | [3.1 d](/filings/0001628280-26-054195.md) | [3.2](/filings/0000016058-25-000087.md) | [7.1 d](/filings/0001628280-26-003026.md) | [154 d](/filings/0001628280-26-026802.md) | [4.6 d](/filings/0001628280-26-054195.md) | [4.1](/filings/0001628280-26-066827.md) | [4.9 d](/filings/0001628280-26-003026.md) | [3.7 d](/filings/0001628280-26-026802.md) | [4.4 d](/filings/0001628280-26-054195.md) | [4.4](/filings/0001628280-26-066827.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [23.7](/filings/0000016058-24-000030.md) | [23.3](/filings/0000016058-24-000070.md) | [22.9](/filings/0000016058-24-000199.md) | [22.4](/filings/0000016058-25-000032.md) | [22.5](/filings/0000016058-25-000053.md) | [22.5](/filings/0000016058-25-000087.md) | [22.5](/filings/0001628280-26-003026.md) | [22.4](/filings/0001628280-26-026802.md) | [22.2](/filings/0001628280-26-066827.md) | [22.1](/filings/0001628280-26-003026.md) | [22.2](/filings/0001628280-26-026802.md) | [22.3](/filings/0001628280-26-066827.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 22,211,835 at 2026-10-16, from the cover of the [10-Q filed 2026-10-22](/filings/0001628280-26-066827.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.